Introduction
Safety data on zoledronic acid (ZA) administration for osteoporosis suggest potential kidney toxicity; indeed, it is not indicated in patients with impaired renal function. Patients' clinical monitoring usually includes glomerular filtration rate (GFR) evaluation; no study addressed the issue of the early kidney injury.
We evaluated the early (within 3 months) effect of iv ZA on renal function defining the potential role of AKI biomarkers in unveiling subtle damage. 
Patients and Methods
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